MedTrace Logo

Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments

NCT04278326 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-04-20

No results posted yet for this study

Summary

Human papilloma virus (HPV) is responsible of the most common sexually transmitted infection. It can cause severe cancer lesions, of the cervix, vulva, vagina, penis and oropharynx. The International Agency for Cancer Research of World Health Organization (WHO) classified a dozen of HPV related high-risk cancer types, and recognized cervical cancer as the most common HPV-related disease. HPV 16 and 18 are responsible for 70% of cervical cancers.

Due to the few symptoms of cervical cancer, women are often diagnosed with advanced state. Current treatments imply cervical conisation or hysterectomy, with or without lymphadenectomy and or radiotherapy, or chemotherapy.

However, few pharmacological options are available against oncogenic papilloma viruses and thus against recurrences The aim of this project is to develop relevant organoids models from patient biopsies that will be used to identify biomarkers and evaluate in a closest preclinical setting novel nucleic acids based therapeutic strategy for HPV-cervical-vaginal dysplasia and cancers.

Conditions

Interventions

PROCEDURE

Vaginal Biopsy

1. Vaginal biopsies 2. Additional cervical and vaginal biopsies 3. Non invasive cervico-vaginal swab like a smear

Sponsors & Collaborators

  • CNRS - Pr Chantal PICHON

    collaborator UNKNOWN

  • Centre Hospitalier Régional d'Orléans

    lead OTHER

Principal Investigators

  • Souhail ALOUINI, M.D.,Ph.D. · CHR Orléans

  • Chantal PICHON, Ph.D. · Centre National de la Recherche Scientifique, France

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-21
Primary Completion
2021-12-21
Completion
2021-12-21

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04278326 on ClinicalTrials.gov